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Porcine reproductive and respiratory syndrome (PRRS) is considered one of the most
relevant diseases of swine. The condition is caused by PRRS virus (PRRSV), an extremely
variable virus of the Arteriviridae family. Its heterogeneity can be responsible, at least
partially, of the poor cross-protection observed between PRRSV isolates. Neutralizing
antibodies (NAs), known to play a role in protection, usually poorly recognize heterologous
PRRSV isolates, indicating that most NAs are strain-specific. However, some pigs
develop broadly reactive NAs able to recognize a wide range of heterologous isolates.
The aim of this study was to determine whether PRRSV isolates that induce broadly
reactive NAs as determined in vitro are able to confer a better protection in vivo. For this
purpose two in vivo experiments were performed. Initially, 40 pigs were immunized with a
PRRSV-1 isolate known to induce broadly reactive NAs and 24 additional pigs were used
as controls. On day 70 after immunization, the pigs were divided into eight groups
composed by five immunized and three control pigs and exposed to one of the eight
different heterologous PRRSV isolates used for the challenge. In the second experiment,
the same experimental design was followed but the pigs were immunized with a PRRSV-1
isolate, which is known to generate mostly strain-specific NAs. Virological parameters,
specifically viremia and the presence of challenge virus in tonsils, were used to determine
protection. In the first experiment, sterilizing immunity was obtained in three groups,
prevention of viremia was observed in two additional groups, although the challenge virus
was detected occasionally in the tonsils of immunized pigs, and partial protection,
understood as a reduction in the frequency of viremia compared with controls, was
recorded in the remaining three groups. On the contrary, only partial protection was
observed in all groups in the second experiment. The results obtained in this study confirm
that PRRSV-1 isolates differ in their ability to induce cross-reactive NAs and, although
other components of the immune response might have contributed to protection, pigsorg July 2021 | Volume 12 | Article 6911451
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broadly reactive NAs might play a role in protection against heterologous reinfections.Keywords: porcine reproductive and respiratory syndrome virus, broad neutralization, neutralizing antibody, cross-
protection, in vivo protectionINTRODUCTION
Porcine reproductive and respiratory syndrome (PRRS) remains
one of the most important diseases of swine. The condition is
characterized by reproductive failure in sows and boars and
respiratory disease in growing pigs, leading to important
economic losses in the vast majority of pork-producing
countries (1). The etiological agent of PRRS is a small,
enveloped, RNA virus, commonly known as porcine
reproductive and respiratory syndrome virus (PRRSV), which
has been recently classified in the genus Betaarterivirus within the
family Arteriviridae in the order Nidovirales (2). The huge
genomic variability of PRRSV isolates has led to their
classification into two different species: Betaarterivirus suid 1,
known as PRRSV-1, which predominates in European countries,
and Betaarterivirus suid 2, known as PRRSV-2, widely spread in
American and Asian countries (3). Even more, a significant
genomic variability has been described within each species, and
several subtypes and lineages have been identified (3–5). Genomic
variability translates into high antigenic variability, which is
considered as one of the main factors, which could explain the
poor or, in the best case, the partial cross-protection observed
upon heterologous virus exposure (6–9).
Although the key elements of the immune response against
PRRSV involved in protection are not completely elucidated,
both humoral and cell-mediated immunity seem to play a role
(10). Thus, animals with a high proportion of PRRSV-specific
IFN-g secreting cells (IFN-g SC) clear the virus after infection
faster than animals with a poor cell-mediated immune response
(11, 12) and the frequency of IFN-g; SC is usually higher in
protected pigs than in unprotected pigs (13). Even more,
vaccinated and challenged pigs can be protected in the absence
of neutralizing antibodies (NAs), supporting the notion that cell-
mediated immunity can confer protection (14). Nevertheless, it is
also well accepted that PRRSV-specific NAs play a role in
protection, as it has been proven in passive transfer studies in
which the sole presence of NAs has been sufficient to confer
protection against reproductive failure, viremia, or even infection
to naïve gestating sows (15) and to prevent viremia and even
infection in growing pigs, although in a dose-dependent
manner (16).
However, the development of PRRSV-specific NAs and IFN-g
SC is considered to be slow (10). Besides, and even more
important, PRRSV variability can condition the ability of the
previously generated immunity to recognize heterologous
strains. As regards cell-mediated immunity, whereas some
studies report broad cross-reactivity of PRRSV-specific IFN-g
SC (17), others indicate huge variability in the recognition of
heterologous strains by IFN-g SC (18, 19). This effect is more
pronounced in the case of the humoral immune response, andorg 2particularly of NAs. Thus, several studies carried out with both
PRRSV-1 and PRRSV-2 have demonstrated that NA cross-
reactivity in seroneutralization (SN) assays is very limited, even
in the case of closely related isolates, indicating that most NAs
generated upon infection are strain-specific and do not recognize
heterologous viruses (20–22).
Nonetheless, field and experimental evidences indicate that a
small proportion of sera contain broadly reactive NAs able to
recognize and neutralize heterologous viruses. Thus, in a recent
immunization and challenge study, 1% of the vaccinated pigs
developed NAs able to recognize efficiently six genetically diverse
viruses in SN assays (22). In addition, a small proportion of field
sera obtained from sows in PRRSV-unstable farms exhibited
neutralizing activity against diverse PRRSV, including PRRSV-1
and PRRSV-2 isolates (23). Both studies indicate the positive
effect of repeated exposures to heterologous viruses in the
generation of broadly reactive NAs against PRRSV. Besides,
there are studies that indicate the individual properties of the
PRRSV to which the pigs are exposed, which might also play a
role in the induction of broadly reactive NAs (21, 24). Yet, the
proportion of PRRSV isolates able to induce broadly reactive
NAs, at least in the case of PRRSV-1, seems to be very low. Thus,
in a study carried out by Martinez-Lobo et al. (21), 29 PRRSV-1
monospecific hyperimmune sera were generated and confronted
to a panel of 39 different PRRSV-1 isolates in SN assays. The
results of that study indicate that only around 10% of the sera
produced exhibited a significant level of cross-reactivity and were
able to recognize and neutralize, at least to some extent, most of
the viruses of the panel. Only three sera recognized all viruses
with geometric mean of the titer (GMT) of NAs higher than 4
log2 (i.e., 1:16). On the contrary, up to 35% of the sera generated
exhibited a GMT of NAs lower than 2 log2 and recognized poorly
many of the isolates used in the SN assays. The ability to induce
broadly reactive NAs might be relevant for the induction of a
protective immune response. However, up to date, it is unclear
whether cross-reactivity in SN assays carried out in vitro
correlates with protection in vivo. As a consequence, the aim
of this study was to determine whether PRRSV isolates that
induce broadly reactive NAs in vitro are able to confer a better
protection in vivo upon exposure to heterologous strains than
PRRSV isolates that induce mostly strain-specific NAs.MATERIALS AND METHODS
Virus Isolates and Cell Cultures
Two PRRSV-1 isolates were selected for the immunization of
pigs in this study. The selection of those viruses was based on the
results of a previous study in which the cross-reactivity of NAsJuly 2021 | Volume 12 | Article 691145
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measured in vitro in SN assays against a panel of 39 viruses
(21). The first isolate selected, Sp-3a, induced broadly reactive
NAs in that study. The breadth of the monospecific sera
generated was 100% (i.e., it was able to neutralize, at least to
some extent, all viruses of the panel) and its potency is high, with
a GMT of NAs of 6.17 log2. On the contrary, the second isolate
selected, EU-11a, did not induce broadly reactive NAs. Its
monospecific serum was able to recognize only 80% of the
viruses with a GMT of NAs of 1.36 log2.
Both isolates were cultured and titrated in MARC-145, a cell
clone derived from MA-104 cell line, highly permissive for
PRRSV infection (25). MARC-145 cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco,
Invitrogen) supplemented with 10% fetal bovine serum (FBS)
(Gibco, Invitrogen) and 1× antibiotic-antimycotic mixture (i.e.,
100 IU penicillin/ml, 100 µg streptomycin/ml, and 0.25 µg
fungizone/ml) (Gibco, Invitrogen) at 37°C in an atmosphere
with 5% CO2. MARC-145 monolayers with approximately 90%
confluency were infected with one of the selected PRRSV isolates
and kept in culture until cytopathic effect (CPE) reached
approximately 80% to 90%. Then, after three cycles of freezing
and thawing, the cultures were clarified by centrifugation. Virus
titers were determined as described by Scortti et al. (26). Viral
titers were calculated following the method developed by Reed
and Muench (27) and expressed as tissue culture infectious doses
50 (TCID50)/ml.
Nine different heterologous PRRSV isolates were selected for
challenge (Table 1). Those viruses were selected on the basis of
genetic distance of the genome region coding for major envelope
proteins (Table 2) and on previous cross-reactivity results in SN
assays (Table 1). PRRSV isolates used for challenge were
cultured and titrated in primary cultures of porcine alveolar
macrophages (PAMs) prepared as previously described (28),
with the exception of PRRSV-2 AM-5 isolate that was
propagated in MARC-145 cell cultures prepared as described
above. However, when these viruses were used for SN assays,
they were cultured in MARC-145 cell line as previously
described. Only viruses exhibiting obvious CPE in MARC-145
cell line were used in this study.
Animals and Experimental Design
A total of one hundred and twenty-eight 10-week-old cross-bred
pigs from a herd free of PRRSV and with no measurable PRRSV
serum antibody titers were used in two different experiments. All
experimental procedures were approved by the Animal Ethics
Committee of Complutense University. In each experiment, 64
pigs were used. In experiment A, after an acclimatization period
of 7 days, 40 randomly selected pigs were immunized by the
intramuscular (IM) route three times 3 weeks apart with 105
TCID50 of Sp-3a isolate, whereas the remaining 24 pigs were kept
as controls. In experiment B, the same protocol was followed
using EU-11a as immunization virus.
Four weeks after the last immunization, the pigs of each
experiment were randomly divided into eight groups composed
by five PRRSV-immunized and three control pigs and were
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Martı́nez-Lobo et al. Broadly NAs in PRRSV Protectionexposed intranasally (IN) to 5 ml of the clarified supernatant of a
PRRSV-infected PAM culture containing a total of 105 TCID50 of
one of the PRRSV isolates selected for challenge.
Every day, from 3 days before challenge until 10 days post-
challenge, rectal temperatures were measured. In addition,
clinical signs were evaluated daily following a previously
published score (29).
Blood samples were collected in serum-clot vacuum tubes on
the day of each immunization (i.e., D0, D21, and D42 of the
experiment), the day of the challenge (i.e., D70 of the
experiment), and every 3 days thereafter until D91 (i.e., day 21
after the challenge). Serum samples were stored at −80°C until
used for virus detection and for the determination of
homologous and heterologous PRRSV NA titers. Twenty-one
days after the challenge (i.e., D91 of the experiment), all pigs
were euthanized, and a complete necropsy was performed. At
necropsy, lungs were collected and examined to evaluate the
presence and severity of macroscopic lung lesions following a
previously published score (30). Besides, tonsils were collected
and stored at −80°C until used for virus isolation and viral
RNA sequencing.
Virus Isolation and Titration
Samples were processed as previously described (28) and used to
inoculate monolayers of PAM or MARC-145 cells, depending on
the isolate considered, in quadruplicate. After 90 min at 37°C to
facilitate adsorption, the monolayers were washed with DMEM
and fresh DMEM supplemented with 10% FBS and 3×
antibiotic–antimycotic mixture was added. The cells were
incubated for 6 days at 37°C, in a humidified atmosphere
containing 5% CO2 and checked for CPE on days 4, 5, and 6
post-inoculation. As a positive control, strain 5710 was added to
DMEM to a final concentration of 104, 103, and 102 TCID50/ml
(i.e., 103, 102, and 10 TCID50/well). Only batches of PAM with a
minimum sensitivity to infection of at least 50% of the wells, to
which 10 TCID50 were added, were used. Virus-free DMEM or
FBS were used as negative controls. If CPE was observed, reverse
transcription polymerase chain reaction (RT-PCR) was carried
out to confirm the presence of PRRSV-1 (31) or PRRSV-2 (32).
Virus titers were determined as described by Scortti et al.
(26).Titers were calculated using the method developed by
Reed and Muench (27) and expressed as TCID50/g for tonsil
samples or TCID50/mL for serum samples.Frontiers in Immunology | www.frontiersin.org 4PRRSV Sequencing
For determining whether the virus isolated from tonsils was the
immunization or the challenge PRRSV isolate, ORF5 from
positive samples was amplified and sequenced. For that
purpose, total RNA was obtained using QIAmp® Viral RNA
Mini kit (Qiagen) following the manufacturer’s instructions.
Then, PRRSV ORF5 was amplified by RT-PCR using a
commercial kit (SuperScript III OneStep RT-PCR platinum
TaqHiFi® , Invitrogen), following the manufacturer ’s
instructions. For this purpose, two different pairs of primers
were used, one to amplify all PRRSV-1 viruses and another one
to amplify the PRRSV-2 isolate used in the study (31, 32). RT-
PCR products were purified using a commercial kit (QIAQuick®
Purification Gel Kit, Qiagen) following the manufacturer’s
instructions. Individual sequences of both strands of the PCR
products were determined with the same pair of primers used for
RT-PCR, amplifying the samples by asymmetric PCR with
fluorescent terminators and analyzing the products by
electrophoresis on an ABI prism 310 Genetic Analyzer
(Applied Biosystems). Sequences were manually corrected,
purged of errors, and a bioinformatics analysis was performed.
Sequences were aligned using Clustal Omega software (33).
Serological Assays
PRRSV-specific antibodies in serum samples were determined
using a commercial ELISA test (HerdChek PRRS ELISA 2XR,
IDEXX Laboratories, Inc.).
To carry out SN assays, all sera were heat inactivated at 56°C
for 30 min. Then two-fold dilutions of each serum were prepared
using DMEM as diluent in 96-well tissue culture plates. Then
50 µl of a viral suspension of the same stock used for the
immunization or for challenge containing 100 TCID50 of the
appropriate PRRSV isolate prepared in DMEM were added to 50
µl of each serum dilution. Serum–viral mixtures were incubated
for 1 h at 37°C in a humidified atmosphere containing 5% CO2.
Thereafter, 100 µl of a cell suspension containing 1 ×104 MARC-
145 cells/well in DMEM supplemented with 10% heat inactivated
FBS was added to the plates that were incubated at 37°C in a
humidified atmosphere containing 5% CO2 for 6 days. All
samples were analyzed in duplicate. The culture plates were
examined for CPE on days 4, 5, and 6 post-inoculation. The titers
were expressed as log2 of the reciprocal of the serum dilution that
completely inhibited viral replication in 50% of the wells.TABLE 2 | Pairwise comparison of the nucleotide sequences of ORFs 2, 3, 4, 5, 6 and 2-6 of the PRRSV isolates used for immunization and challenge in Experiments
A and B.
Challenge isolate Immunization isolate Sp-3a Challenge isolate Immunization isolate EU-11a
ORF2 ORF3 ORF4 ORF5 ORF6 ORF2-6 ORF2 ORF3 ORF4 ORF5 ORF6 ORF2-6
AM-5 63.6 62.2 65.5 61.0 69.1 64.6 AM-5 60.0 62.0 64.8 61.6 69.1 64.3
EU-17 86.5 83.4 84.9 86.1 86.0 85.6 EU-17 82.8 85.2 85.1 85.4 87.5 86.2
Sp-27 89.2 85.9 92.0 90.0 97.5 91.6 Sp-27 83.4 84.4 90.9 89.2 97.3 90.4
EU-5 93.8 93.7 94.9 93.2 96.1 94.1 EU-5 90.0 97.8 97.8 97.6 99.2 97.0
EU-15 89.7 87.3 87.1 80.6 91.5 89.2 EU-15 84.5 88.5 87.1 80.3 90.0 88.9
Sp-22 91.0 90.6 90.9 92.4 97.1 92.1 Sp-22 86.4 90.4 89.8 89.4 95.9 91.1
Sp-29 90.6 85.8 85.5 90.5 93.6 89.7 Sp-29 86.0 89.5 86.9 89.4 93.6 90.3
EU-11 86.5 92.9 93.1 92.2 96.5 92.8 Sp-3 86.5 92.9 93.1 92.2 96.5 92.8July 2021 | Volume 12 | Article 691145
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The occurrence of clinical signs and macroscopic lung lesions
were evaluated for significance using Kruskal–Wallis non-
parametric and Mann–Whitney U tests. A Student’s t test was
used to assess significance in differences in rectal temperature
before and after the challenge. GMT of NAs against the viruses
used for immunization and challenge was estimated. Differences
in GMT of NAs obtained for the different isolates were analyzed
using Kruskal-Wallis non parametric and Mann-Whitney U
tests. Differences in viral titers were evaluated for significance
by one-way analysis of variance and Duncan’s multiple range
test. In addition, differences in the proportion of positive samples
were assessed for significance by the two-tailed Fisher’s exact test.
Finally, the existence of a booster in NAs upon challenge was
analyzed for significance by using Friedman and Dunn’s multiple
comparison tests. All statistical tests were carried out with
GraphPad Prism software, and results were considered as
statistically significant when p value is less than 0.05.RESULTS
Serological Response to Immunization
On D0, all pigs were seronegative for PRRSV-specific systemic
IgGs measured by ELISA test. However, from D21 to the end of
the study, all animals remained seropositive in both experiments.
In the same way, no NAs were detected on the day of the first
immunization in any of the pigs. However, on D21, most of the
animals had detectable, although generally low, titers of NAs
against the immunization PRRSV isolate, with GMTs of NAs of
1.97 log2 in the case of Sp-3a (i.e., Experiment A) and 1.31 log2 in
the case of EU-11a (i.e., Experiment B) (Figure 1). At the time of
the third immunization (i.e., D42), homologous NA titers have
raised slightly and steadily in both experiments (A and B),
reaching GMTs of 2.73 log2 and 1.77 log2 for Sp-3a and EU-
11a, respectively. However, on the day of challenge (i.e., D70), in
experiment A, the GMT of NAs against Sp-3a has raised sharply
(i.e., GMT of 5.15 log2), whereas in the case of experiment B, theFrontiers in Immunology | www.frontiersin.org 5GMT of NAs against EU-11a have increased only moderately
(i.e. GMT of 2.06 log2). The differences in NA titers against the
immunization PRRSV isolate on the day the third immunization
(i.e. D42) and the day of challenge (i.e. D70) were statistically
significant (p < 0.05) between the experiments.
Evaluation of Clinical Signs and Lesions
No remarkable clinical signs were observed after the challenge in
any of the pigs, regardless if they were immunized or control
pigs, neither in experiment A nor in experiment B. In the same
way, rectal temperatures remained, with very few exceptions,
within normal limits for pigs of that age after the challenge, and
no statistically significant differences were observed between
groups, between immunized and controls, or before and after
viral exposure. Finally, no macroscopic lung lesions were
observed at necropsy in any of the pigs, regardless if they were
immunized or control pigs or the virus used for the challenge,
neither in experiment A nor in experiment B.
In experiment B, one of the immunized pigs died on D56 of
the experiment because of an incarcerated umbilical hernia.
Consequently, only four immunized pigs were assigned to
group B.7 at the time of the challenge.
PRRSV Detection in Clinical Samples
All pigs were negative to PRRSV in serum samples on the day of
the first immunization (i.e., D0 of the experiment). Then, on D21
(i.e., the day of the second immunization), all serum samples
obtained from immunized pigs in both experiments (A and B)
were positive by virus isolation. However, on D42 (i.e., the day of
the third immunization), no virus was detected in any
serum samples.
The results of the isolation of PRRSV from the serum samples
obtained from the previously immunized and control pigs in
experiments A and B on the day of challenge (i.e., D70) and
afterward are shown in Tables 3.1, 3.2, 4.1 and 4.2. As can be
seen in Tables 3.1, 3.2, in experiment A (i.e. pigs immunized
with PRRSV isolate Sp-3a), viremia could not be detected at any
time after the challenge in any of the immunized pigs in five of
the eight experimental groups. Conversely, viremia was detected
in the immunized pigs of the other three experimental groups
(i.e., groups A.2, A.3, and A.4). However, the frequency of
detection was much lower than that in the control pigs and in
most cases limited to the first few days after challenge and/or to
some pigs. On the contrary, PRRSV was detected in serum
samples from all control pigs from all experimental groups on
most sampling days. Differences in the frequency of viremia
between immunized and control pigs were statistically significant
from day 3 post-challenge in all groups in which viremia was
never detected in immunized pigs at any time post-challenge (p <
0.05). In addition, differences were also statistically significant in
group A.2 from day 6 to day 18 post-challenge, in group A.4
from day 9 to day 21 post-challenge, and in group A.3 on day 9
post-challenge (p < 0.05). Conversely, no statistically significant
differences were detected in the viral titer in serum samples
between immunized and control pigs with the only exception of
pigs of group A.3 on day 3 post-challenge (1.70 TCID50/ml in
immunized pigs versus 3.29 TCID50/mL in controls, p < 0.05).FIGURE 1 | Dynamics of development of NAs against the PRRSV isolate
used for immunization in Experiment A and Experiment B. Statistically
significant differences (p < 0.05) are marked with a * symbol.July 2021 | Volume 12 | Article 691145
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PRRSV-1 EU-11a in experiment B can be considered very poor.
Thus, viremia was frequently detected at most time-points after
challenge in immunized pigs (Tables 4.1, 4.2). In the same way,
control pigs show a pattern of viremia similar to that observed in
experiment A, with most pigs positive at all sampling days. The
differences in the proportion of viremic pigs between immunized
and control pigs were not statistically significant with the
exception of group B.5 on days 3, 18, and 21 post-challenge
and group B.8 on day 6 post-challenge (p < 0.05). In the same
way, viral titers in viremic pigs were similar between immunized
and controls except in group B.2 on day 6 post-challenge and in
group B.8 on day 12 post-challenge (p < 0.05).
Viral load in blood samples of controls pigs was compared
between experiments. Although globally viral titers tended to be
higher in experiment B, differences were statistically significant
only in pigs exposed to AM-5 and Sp-22 (p < 0.05). Nonetheless,
when viral titers were compared day by day, viral titers were
significantly higher in experiment A in some days and in
experiment B in some others (data not shown).
The results of PRRSV detection and identification in tonsils in
experiments A and B are summarized in Tables 5.1, 5.2. As it can
be observed in the tables, PRRSV could be detected in the tonsils
of a variable number of immunized pigs in all groups. However,
sequencing of the viruses identified indicated that in three of theFrontiers in Immunology | www.frontiersin.org 6eight experimental groups (i.e., groups A.1, A.5, and A.6), the
virus present in tonsils was the immunization isolate, whereas in
the other five groups, the virus present in tonsils was the
challenge virus (i.e., groups A.2, A3, A.4, A.7, and A.8). As
expected, the challenge PRRSV was found in the tonsils of most
of the previously immunized pigs of the groups in which the
viremia was detected. However, and remarkably, the challenge
virus was also found in one immunized pig of group A.8 and in
two immunized pigs of group A.7, in which viremia was never
recorded, suggesting that protection achieved in those animals
was not sterilizing.
On the contrary, most of the tonsils obtained from pigs
immunized with EU-11a in experiment B were positive for
PRRSV challenge isolate.
Finally, PRRSV was found in the tonsils of all control pigs,
regardless the study considered or the group they belonged to.
Cross-Reactivity of NAs at the Time of
Challenge and Evolution of Homologous
and Heterologous NAs
The GMT of NAs against the PRRSV isolates used for
immunization and challenge for each group in experiment A is
depicted in Figure 2. As it can be observed in the figure, GMT of
NAs against Sp-3a was quite similar between experimental
groups the day of the challenge and ranged from 4.77 log2 inTABLE 3.1 | Virus isolation from serum samples collected in Experiment A (pigs immunized with Sp-3a).
Days
post-challenge
Group A.1 (EU-11) Group A.2 (AM-5) Group A.3 (EU-17) Group A.4 (Sp-27)
Immunized Controls Immunized Controls Immunized Controls Immunized Controls
D0 0/5 (-)* 0/3 (-) 0/5 (-) 0/3 (-) 0/5 (-) 0/3 (-) 0/5 (-) 0/3 (-)
D3 0/5a (-) 3/3 (1.89 ± 0.54) 1/5 (1.66) 3/3 (1.67 ± 0.29) 4/5 (1.70 ± 0.09)b 3/3 (3.29 ± 0.06) 4/5 (1.67 ± 0.24) 3/3 (2.28 ± 0.63)
D6 0/5a (-) 3/3 (2.11 ± 0.54) 0/5a (-) 3/3 (1.67 ± 0.29) 1/5 (3.23) 2/2c (3.05 ± 0.55) 2/5 (2.00 ± 0.71) 3/3 (3.05 ± 0.42)
D9 0/5a (-) 3/3 (1.55 ± 0.09) 0/5a (-) 3/3 (1.55 ± 0.09) 0/5a (-) 3/3 (2.70 ± 0.67) 0/5a (-) 3/3 (2.72 ± 0.68)
D12 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 3/3 (1.83 ± 0.58) 1/5 (1.66) 3/3 (1.89 ± 0.54 0/5a (-) 3/3 (2.28 ± 0.25
D15 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 3/3 (2.00 ± 0.50) 1/5 (1.50) 3/3 (2.27 ± 1.20) 0/5a (-) 3/3 (2.22 ± 0.48)
D18 0/5a (-) 3/3 (1.55 ± 0.09) 0/5a (-) 3/3 (1.55 ± 0.09) 1/5 (1.66) 3/3 (2.72 ± 0.85) 0/5a (-) 3/3 (1.67 ± 0.29)
D21 0/5a (-) 3/3 (1.50 ± 0.00) 1/5 (1.50) 3/3 (1.78 ± 0.48) 1/5 (1.66) 3/3 (1.80 ± 0.38) 0/5a (-) 3/3 (1.67 ± 0.29)July 2021 | Volume 12*Frequency of isolation of PRRSV from serum samples. Mean titer and standard deviation are indicated in parentheses.
aIndicates statistically significant differences in the frequency of isolation between the immunized and control pigs.
bIndicates statistically significant differences in the viral titers in serum samples between the immunized and control pigs.
cThe serum sample of one of the control pigs was not available on day 6 post-challenge.TABLE 3.2 | Virus isolation from serum samples collected in Experiment A (pigs immunized with Sp-3a).
Days post-challenge Group A.5. (EU-5) Group A.6. (EU-15) Group A.7. (Sp-22) Group A.8. (Sp-29)
Immunized Controls Immunized Controls Immunized Controls Immunized Controls
D0 0/5 (-)* 0/3 (-) 0/5 (-) 0/3 (-) 0/5 (-) 0/3 (-) 0/5 (-) 0/3 (-)
D3 0/5a (-) 3/3 (2.33 ± 0.33) 0/5a (-) 3/3 (2.24 ± 0.37) 0/5a (-) 3/3 (3.72 ± 0.26) 0/5a (-) 3/3 (3.39 ± 0.79)
D6 0/5a (-) 3/3 (1.83 ± 0.44) 0/5a (-) 3/3 (2.78 ± 0.63) 0/5a (-) 3/3 (2.22 ± 0.38) 0/5a (-) 3/3 (2.61 ± 0.09)
D9 0/5a (-) 3/3 (2.22 ± 0.48) 0/5a (-) 3/3 (1.78 ± 0.48) 0/5a (-) 3/3 (2.16 ± 0.44) 0/5a (-) 3/3 (2.22 ± 0.35)
D12 0/5a (-) 3/3 (1.67 ± 0.29) 0/5a (-) 3/3 (2.16 ± 0.01) 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 3/3 (2.00 ± 0.50)
D15 0/5a (-) 3/3 (1.77 ± 0.20) 0/5a (-) 3/3 (1.83 ± 0.29) 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 2/3 (2.00 ± 0.71)
D18 0/5a (-) 3/3 (1.94 ± 0.63) 0/5a (-) 3/3 (1.55 ± 0.09) 0/5a (-) 3/3 (1.55 ± 0.09) 0/5a (-) 3/3 (1.83 ± 0.29)
D21 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 3/3 (1.50 ± 0.00) 0/5a (-) 3/3 (1.74 ± 0.42) 0/5a (-) 3/3 (1.83 ± 0.58)*Frequency of isolation of PRRSV from serum samples. Mean titer and standard deviation are indicated in parentheses.
aIndicates statistically significant differences in the frequency of isolation between the immunized and control pigs.| Article 691145
TABLE 4.1 | Virus isolation from serum samples collected in Experiment B (pigs immunized with EU-11a).
oup B.1. (Sp-3) Group B.3. (EU-17 Group B.4. (Sp-27)
Controls ized C ls Immunized Controls
0/3 (-) (-) ) 0/5 (-) 0/3 (-)
52) 3/3 (2.39 ± 0.34) ± 1.05) 2/3 (2 0.17) 4/5 (1.86 ± 0.61) 3/3 (1.53 ± 0.03)
51) 3/3 (2.61 ± 0.92) ± 1.00) 3/3 (3 0.58) 5/5 (2.03 ± 0.91) 3/3 (2.83 ± 1.44)
3/3 (2.11 ± 0.51) ± 0.90) 3/3 (3 0.38) 4/5 (2.54 ± 0.71) 3/3 (2.72 ± 1.11)
20) 3/3 (1.89 ± 0.067) ± 0.91) 3/3 (2 1.20) 3/5 (1.72 ± 0.26) 3/3 (2.78 ± 1.11)
71) 3/3 (2.28 ±.0.75) ± 0.95) 3/3 (2 1.02) 2/5 (3.00 ± 0.94) 3/3 (2.24 ± 0.64)
05) 3/3 (1.88 ± 0.39) ± 0.53) 3/3 (2 0.76) 1/5 (1.50) 3/3 (2.44 ± 1.63)
00) 2/3 (2.42 ± 1.29) ± 0.42) 2/3 (2 0.71) 1/5 (2.66) 2/3 (2.11 ± 0.63)
amples. Mean titer and standard devia
e viral titers in serum samples betwee
ples collected in Experiment B (pig
up B.5. (EU-5) roup B.7. (Sp-22) Group B.8. (Sp-29)
Controls ed Con s Immunized Controls
0/3 (-) ) 0/ 0/5 (-) 0/3 (-)
3/3 (1.55 ± 0.09) 5 0.33) 3/3 (2.6 0.09) 4/5 (2.53 ± 0.66) 3/3 (2.22 ± 0.63)
3/3 (3.11 ± 0.51) 3 0.67) 3/3 (3.7 0.77) 0/5a (-) 3/3 (3.84 ± 0.43)
3/3 (2.05 ± 0.58) 2 0.00) 3/3 (3.2 0.55) 1/5 (1.66) 3/3 (2.73 ± 0.77)
9) 3/3 (2.00 ± 0.34) 3 0.11) 3/3 (2.7 0.20) 4/5 (1.83 ± 0.56)b 3/3 (3.83 ± 0.58)
2/3 (2.25 ± 1.06) 3 0.80) 3/3 (2.5 1.54) 2/5 (1.58 ± 0.11) 3/3 (2.61 ± 0.35)
2/3 (2.17 ± 0.23) 3 0.59) 3/3 (1.9 0.58) 1/5 (4.00) 3/3 (2.05 ± 0.42)
2/3 (1.83 ± 0.24) 2 0.24) 3/3 (1.6 0.29) 1/5 (2.00) 1/3 (2.33 ± NA)
amples. Mean titer and standard devia
e frequency of isolation between the i
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/5 (-) 0/3 (-) 0/5 (-
6 ± 0.20) 3/3 (1.55 ± 0.09) 4/4 (2.68 ±
9 ± 0.34) 3/3 (3.22 ± 0.38) 3/4 (2.27±
3 ± 0.00) 3/3 (2.22 ± 0.63) 3/4 (1.50 ±
7 ± 0.67) 3/3 (2.61 ± 0.35) 2/4 (1.58 ±
0 ± 0.87) 3/3 (2.00 ± 0.34) 4/4 (2.37 ±
3 ± 1.04) 3/3 (2.33 ± 0.33) 2/4 (2.08 ±
2 ± 0.59) 2/3 (1.75 ± 0.12) 2/4 (1.83 ±
e indicated in parentheses.
ized and control pigs.
immunized and control pigs.z
Martı́nez-Lobo et al. Broadly NAs in PRRSV Protectiongroup A.1 to 5.96 log2 in group A.5. However, the GMT of NAs
against the PRRSV isolate used for the challenge was more
variable and ranked from undetectable levels in groups A.2
and A.3 to 2.93 log2 in groups A.5 and A.7. Then, after the
challenge, the GMT of NAs against Sp-3a remained relatively
steady in the groups in which viremia was not observed after
challenge, whereas in groups A.2, A.3, and A.4, in which viremia
was recorded, a slight increase in the GMT of NAs against Sp-3a
was observed. The differences in NA titers immediately before
and after challenge were statistically significant in groups A.3 and
A.4, but not in group A.2 (p < 0.05). Regarding the response of
NAs against the PRRSV isolate used for challenge, remarkable
differences were noted between groups. Thus, in some groups
NAs were barely detectable during the whole experimental
period (i.e., groups A.2 and A.3), in some other groups, the
titers of NAs remained relatively stable (i.e., groups A.1 and A.5),
and in some others, an increased in GMT of NAs was recorded
(i.e., groups A.4, A.6, A.7, and A.8). Nonetheless, differences in
NA titers before and after challenge were statistically significant
only in the case of group A.4 (p < 0.05).
When the GMT of NAs against the challenge virus on D70 of
the experiment (i.e., day of challenge) was compared between
groups in which the challenge virus was never found in
immunized pigs (i.e., groups in which sterilizing immunity was
observed), groups in which viremia was not detected but the
challenge virus was occasionally detected in tonsils and groups in
which viremia was detected upon challenge of immunized pigs, it
was observed that titers were higher in the groups with sterilizing
immunity than in groups in which the challenge virus was
detected in tonsils and both titers were higher than in groups
in which viremia was detected in immunized pigs. However,
differences were statistically significant only between the groups
in which viremia was detected and the groups in which viremia
was never detected, regardless whether challenge virus could be
detected in tonsils or not (Figure 3).
The GMT of NAs against PRRSV isolates used for
immunization and challenge for each group in experiment B is
depicted in Figure 4. In this case, GMT of NAs against EU-11a
were lower than those recorded against Sp-3a in experiment A
and ranged from 1.40 log2 in groups B.5 and B.6 to 3.60 log2 in
group B.2. However, NAs against the challenge isolates wereFrontiers in Immunology | www.frontiersin.org 8undetectable in most cases, and only in group B.5 reached values
close to 2 log2. Then, after challenge, and contrary to what
happened in experiment A, the GMT of NAs against EU-11a
increased in all experimental groups, with statistically significant
differences (p < 0.05), with the only exception of group B.7. The
same phenomenon was observed in the case of the GMT of NAs
against the viruses used for challenge, and in this case, differences
were statistically significant in all experimental groups (p < 0.05).DISCUSSION
Although PRRSV infection is considered to be long-lasting,
infected pigs eventually clear the virus (34), which indicates
that they are capable of mounting an immune response effective
in the resolution of the infection (10). Even more, this immune
response seems to be effective in the prevention of homologous
reinfections (35) and, as least partially, in the prevention of
heterologous infections (7, 8, 36). In this protective immunity,
both cell-mediated and NAs are considered to play a role (14).
However, and despite the crucial role that NAs may play in
the prevention of reinfections, their efficacy is largely
compromised by their generally accepted lack of cross-
reactivity. Nonetheless, in the last few years, the existence of
broadly reactive NAs able to recognize a significant number of
genetically diverse PRRSV has been reported. The generation
of these broadly reactive NAs can be stimulated by multiple
exposures to different viruses over time (9, 23, 37) or derive from
repeated exposures to the same PRRSV isolate (21).
Our hypothesis in the present study was that individual viral
properties might play a role in the induction of broadly reactive
NAs and that those broadly reactive NAs might confer better
protection against reinfections. To test this hypothesis, we
selected two different viruses characterized in a previous study.
The first virus, Sp-3a, induces broadly reactive NAs, whereas the
second one, EU-11a, is a virus that induces mostly monospecific
NAs with a very limited cross-reactivity. These two viruses were
used in two in vivo experiments designed to optimize the
generation of NAs and to test the protection of the immunized
pigs against PRRSV heterologous challenges.TABLE 5.1 | Results of PRRSV RT-PCR and PRRSV isolate identification by sequencing from tonsils collected at necropsy from pigs in Experiment A.
















RT-PCR positive samples (%) 5/5 (100) 5/5 (100) 5/5 (100) 4/5 (80) 4/5 (80) 5/5 (100) 4/5 (80) 4/5 (80)
Immunization virus (%) 5/5 (100) 0/5 (0) 0/5 (0) 1/5 (20) 4/5 (80) 5/5 (100) 2/5 (40) 3/5 (60)
Challenge virus (%) 0/5 (0) 5/5 (100) 5/5 (100) 3/5 (60) 0/5 (0) 0/5 (0) 2/5 (40) 1/5 (20)July 2021 | Volume 12 | ArtTABLE 5.2 | Results of PRRSV RT-PCR and PRRSV isolate identification by sequencing from tonsils collected at necropsy from pigs in Experiment B.
















RT-PCR positive samples (%) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 4/5 (80) 4/4 (100) 4/5 (80)
Immunization virus (%) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0) 0/5 (0) 0/4 (0) 0/5 (0)
Challenge virus (%) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 5/5 (100) 4/5 (80) 4/4 (100) 4/5 (80)icle 691145
Martı́nez-Lobo et al. Broadly NAs in PRRSV ProtectionAs this study was designed as a proof-of-concept to determine
the value of NAs for protection, three immunizations were
carried out in 10-week-old pigs, rather than using the regular
3-week-old pig model and a single viral exposure. We selected
the pigs at the beginning of the growing period because, in our
experience, older pigs tend to develop higher titers of NAs than
younger pigs. Besides, we decided to follow the same protocol of
immunization used in our previous in vitro study, to be able to
compare in vitro and in vivo results. Consequently, we gave the
pigs three immunizations 3 weeks apart. These repeated
exposures were intended to mimic a hyperimmunization
protocol and, theoretically, could have increased the chances of
generating broadly reactive NAs in stimulating affinity
maturation through hypersomatic mutation of antibodiesFrontiers in Immunology | www.frontiersin.org 9directed against conserved neutralizing epitopes, as it has been
previously suggested (23). Finally, 4 weeks after the last
immunization, the pigs were exposed to one of the eight
heterologous PRRSV isolate used in the study.
The protocol followed for immunization and the age of the pig at
the beginning of the study led to the pigs being challenged at the age
of 140 days. In our experience, experimental exposure of pigs to
PRRSV-1 under controlled conditions at that age does not produce
measurable clinical signs, negative effects on productive parameters
or remarkable lung lesions: The same phenomenon has recently
been described for PRRSV-2 viruses (12). Thus, as expected, none of
the pigs, neither immunized nor controls, showed any remarkable
clinical signs in any of the two experiments. In the same way, rectal
temperatures remained, with very few exceptions, within normalFIGURE 2 | GMT of NAs against the immunization and challenge PRRSV isolates in immunized pigs and against challenge PRRSV isolate in control pigs in the eight
groups included in the study from the day of challenge to the end of the experiment in Experiment A. The graph illustrates the GMT ± standard deviation.July 2021 | Volume 12 | Article 691145
Martı́nez-Lobo et al. Broadly NAs in PRRSV Protectionlimits for pigs of their age during the post-challenge period, and no
macroscopic lesions were observed in the lungs at necropsy. As a
consequence, the level of protection upon challenge was estimated
using virological parameters, specifically the development of viremia
and the establishment of a carrier state in the tonsils at the end of the
experiments. Those virological parameters were selected because
they are considered the most reliable indicators of protection in pigs
of that age (12). The virological results were compared between
immunized and control pigs and between experiments. In these
comparisons, an unexpected finding was that viral load in blood
samples was higher in experiment B. Although it can be speculated
that these results indicate a higher susceptibility to infection of the
pigs used in experiment B, all animals were purchased from the
same farm and had the same genetic background and were
randomly distributed between groups. Besides, when all data were
analyzed together, differences in viral titer were statistically
significant only in two groups (i.e., pigs challenged with AM-5
and with Sp-22). No statistically significant differences were found
between control groups in the remaining six challenge viruses, and
when differences were analyzed day by day, additional statistically
significant differences were detected but sometimes favored the pigs
of experiment A and some others pigs of experiment B (data not
shown). Thus, a general pattern could not be established, and we
believe that these differences might be related to the low number of
pigs used per control group and that they do not affect significantly
to the general results of the study and their interpretation.
The results obtained indicate that pigs initially immunized
with PRRSV isolate Sp-3a achieve a remarkable level of
protection upon a secondary exposure to a heterologous
PRRSV. Thus, in three of the eight groups in experiment A,Frontiers in Immunology | www.frontiersin.org 10immunity developed upon immunization was considered
sterilizing as no virus was found in serum samples or in tonsils
at necropsy. The achievement of sterilizing immunity against a
heterologous exposure is an extremely rare event in the case of
highly variable RNA viruses and, to our knowledge, it has never
been reported for PRRSV-1. On the contrary, although extremely
rare as well, a remarkable level of protection has been recently
described with a centralized immunogen developed using full-
genome sequences of PRRSV-2 (24). Both studies confirm that
very high levels of heterologous protection are possible against
both PRRSV species.
Protection was also notable in two additional experimental
groups in experiment A in which viremia was never detected
upon heterologous challenge. Nonetheless, in those groups,
immunity was not sterilizing, and the challenge virus was detected
in the tonsils of some pigs. This same phenomenon has been
observed in the study by López et al. (16) in which NAs titers from
1:8 to 1:32 were passively transferred to 2-week-old piglets before
they were challenged. We do not know how the heterologous
viruses used in our study reached the tonsils despite being never
detected in serum, but several explanations are possible. One
possibility is that viremia might have been established but the
maximum viral load reached was below the detection threshold of
the technique used in our study. We selected virus isolation for
PRRSV detection to make sure that we detected only viable virus,
but the downside of this approach is that the sensitivity of detection
is lower than that of RT-qPCR technique. Nonetheless, previous
studies show that although the frequency of viremia is lower in
vaccinated pigs, the amount of virus in the serum of pigs that
become viremic is generally not much lower than the viral load in
unvaccinated pigs (6, 8, 36). In consequence, we believe that the
sensitivity of detection is unlikely to be responsible for the lack of
virus detection in serum samples in our study. Another possibility is
that the presence of an immune response at the time of challenge
might have prevented free-virus viremia and only cell-associated
viremia have occurred in those pigs. The existence of cell-associated
viremia in the absence of free PRRSV in serum has been previously
demonstrated in other studies in which a significant amount of
circulating NAs was present (16) and could explain the arrival of the
virus to lymphoid tissues. Unfortunately, buffy coat was not
obtained in our study and, although we consider this a plausible
and likely explanation, we cannot confirm it or discard it.
Finally, in the remaining three experimental groups in
experiment A, only the classical partial protection was
repeatedly reported in the literature upon detection of
heterologous PRRSV exposure. In fact, these results can be
considered the most likely outcome upon the exposure of
previously infected pigs to a heterologous PRRSV isolate.
Nonetheless, the differences with the results recorded for the
other experimental groups in experiment A are outstanding.
These differences might be explained, at least partially, by the
lack of cross-reactive NAs at the time of challenge. However, it
should be mentioned that the characteristics of the PRRSV
isolates used for the secondary exposure in some of those
groups might have also contributed to the outcome of
infection. Thus, the pigs of group A.2 were exposed to aFIGURE 3 | GMT of NAs against the challenge virus on D70 of the
experiment (i.e day of challenge) in groups in which sterilizing immunity was
observed, groups in which viremia was not detected but the challenge virus
was occasionally detected in tonsils and groups in which viremia was
detected upon challenge of immunized pigs in experiment A. Each box
represents 25–75% of observation. Whiskers above and below of each box
represent the lowest datum still within 1.5 interquartile range (IQR) of the
lower quartile, and the highest datum still within 1.5 IQR of the upper quartile.
Solid line within each box is the median. Statistically significant differences are
highlighted by different letters.July 2021 | Volume 12 | Article 691145
Martı́nez-Lobo et al. Broadly NAs in PRRSV ProtectionPRRSV-2 isolate, and cross-protection between PRRSV-1 and
PRRSV-2 is considered insignificant, as demonstrated in
different studies carried out in adult sows (38, 39), boars (40,
41), and piglets (42, 43). This is probably due to the enormous
genetic divergence between the two PRRSV species (14). On the
other hand, pigs of group A.3 were exposed to the heterologous
PRRSV isolate EU-17, which is an Italian isolate with a relatively
low genomic similarity with Sp-3a. Besides, this isolate has been
classified as an isolate of high virulence based on the severity of
the clinical signs and lesions recorded in a study carried out in 3-
week-old pigs in the respiratory model of the disease (44).
Virulence might be a relevant characteristic because it has been
demonstrated that PRRSV-1 isolates of higher virulence replicate
more efficiently in the host (45, 46) and in a wider range ofFrontiers in Immunology | www.frontiersin.org 11cellular types (47, 48), and it can be speculated that this better in
vivo replication might help to overcome any previously existing
immunity, either humoral or cellular.
On the contrary, in experiment B, previous immunization of
pigs with EU-11a had a limited or very limited effect on the
replication of the heterologous PRRSV isolate. Thus, the
percentage of positive serum samples in immunized pigs
ranged from 22.9% to 85.7%, compared with frequencies of
isolation from 87.7% to 100% in control pigs. This frequency
of detection was, in general, higher than that reported in the
literature when pigs immunized with different commercial
vaccines have been later exposed to virulent challenges [e.g.
32% in vaccinated versus 84% in unvaccinated pigs in the study
by Prieto et al. (8) or 10% to 12.5% in vaccinated versus 82.5% inFIGURE 4 | GMT of NAs against the immunization and challenge PRRSV isolates in immunized pigs and against challenge PRRSV isolate in control pigs in the eight
groups included in the study from the day of challenge to the end of the experiment in experiment B. The graph illustrates the GMT ± standard deviation.July 2021 | Volume 12 | Article 691145
Martı́nez-Lobo et al. Broadly NAs in PRRSV Protectionunvaccinated pigs in the study by Kim et al. (42)]. Consistently,
PRRSV was found in the tonsils of all pigs, regardless the group
they belonged to.
The virus found in the tonsils of pigs in experiment B was the
challenge virus, whereas in experiment A, not only the challenge
virus but also the immunization virus was found, in this last case,
in some non-viremic pigs. However, these results might be biased
because of the method used for virus identification (i.e., ORF5
sequencing by Sanger method). PRRSV is known to persist in
tonsils for prolonged periods of time (34), and different viruses
can coexist in infected pigs for some time, even though
predominant viruses tend to overcome all others and eventually
make them disappear of the host (49). Consequently, it is possible
that some pigs bore the immunization isolate at the time of
challenge, and it became the minor population upon challenge.
Besides, coexistence of different isolates might lead to the
generation of mosaic viruses by recombination (50). Thus,
immunization virus could have been present in tonsils in
experiment B, but only the predominant challenge virus was
detected by sequencing, and some of the detected viruses might
have been recombinant viruses. Next-generation sequencing of
full-genome would have helped to clarify these points but,
unfortunately, it could not be carried out.
Taken together, the results of both experiments indicate that
pigs immunized with Sp-3a controlled more efficiently a
subsequent exposure to a heterologous PRRSV than pigs
immunized with EU-11a. Although the ultimate reasons for
these differences remain unknown, one remarkable difference
between these two viruses is their ability to induce strain-specific
and broadly reactive NAs. Thus, at the time of heterologous
challenge (i.e., D70 of the experiment), the GMT of NAs against
the homologous virus in pigs exposed to Sp-3a was 5.15 log2
compared with 2.06 log2 in the pigs exposed to EU-11a.
However, it has to be bore in mind that one limitation of this
measure is that SN assays have been performed in MARC-145
cell line, which is not a natural target cell for PRRSV. We selected
MARC-145 cell line to carry out the SN assays for several
reasons. First, all NA passive-transfer studies which have
proven the role of NA in protection and have determined the
minimum titer needed for protection in SN assays carried out in
MARC-145 cell line (15, 16). In the same way, our previous study
aimed to determine the existence of differences in the NA
induction ability among PRRSV-1 isolates and used to select
the PRRSV isolates to be used in the present study also used
MARC-145 cell-line for SN assays (21). Thus, the use of this
methodology allowed us to compare our results with previous
studies. Besides, although there are some studies in the literature
that have used PAM cells in SN assays (18, 51, 52), most of the
PRRSV vaccination and challenge studies have used MARC-145
to carry out the SN assays used to determine the titer of NAs (53–
55), and this is an accepted and well-established technique for
the determination of NAs against PRRSV. Nonetheless, MARC-
145 cells contain the simian CD163 instead of the porcine
molecule, and we cannot rule out the possibility that the use of
PAM or other modified porcine cells expressing porcine CD163
and sialoadhesin (Sn) or Siglec 10 (56) would have renderedFrontiers in Immunology | www.frontiersin.org 12slightly different results. Unfortunately, we could not do the
comparison because of the logistical complications of testing a
high number of samples in PAM and to the unavailability of
CD163 and Sn transfected cells in our laboratory.
Nonetheless, we do believe that the differences found between
isolates in their ability to induce both strain-specific and broadly
reactive NAs, although could be qualified, are real, particularly
considering the differences found in protection. We do not know
the reasons why different viruses exhibit different NA-induction
capability, but the ability to induce NAs seems to be an intrinsic
property of PRRSV isolates as it has been described in the
literature for PRRSV-1 (11, 21), as well as for PRRSV-2 (20, 57).
On the other hand, most of the NAs generated upon PRRSV
infection seem to be strain-specific (20–22). However, to confer
protection against heterologous reinfections, a PRRSV isolate
must be able to induce cross-reactive NAs. When we looked at
the cross-reactivity of NAs at the time of challenge, and
consistently with our previous data, it was observed that the
recognition of the heterologous viruses by NAs was better in
experiment A than in experiment B. Thus, in experiment B,
cross-reactive NAs were absent or barely detectable in most
experimental groups. The only remarkable exception was group
B.5, in which the GMT of the titer of NAs against the challenge
virus was 1.64 log2 on D70 of the experiment. On the contrary, in
experiment A, detectable titers of cross-reactive NAs were
detected the day of challenge in six out of the eight
experimental groups, with GMTs ranging from 0.72 to 2.93 log2.
The reasons why broadly reactive NAs are generated upon
PRRSV infection remain undetermined. In our study, it could be
speculated that the significantly lower level of homologous NAs
developed in the pigs of experiment B compared with the pigs of
experiment A (i.e. 2.06 log2 versus 5.15 log2) is the reason for the
lack of cross-reactivity observed in experiment B. However, in
our opinion, the low level of homologous NAs does not fully
explain the lack of cross-reactivity of NAs specific for EU-11a.
We base this statement in two facts. First, in a previous study in
which the homologous titer of a hyperimmune serum against
EU-11a was fixed at 7 log2, heterologous isolates were barely
recognized in SN assays (21). Second, in the present study, the
sera of the few pigs that had homologous titers of NAs between 4
and 6 log2 the day of challenge in experiment B reacted poorly
with the challenge strain (data not shown). Both results indicate
that most NAs generated upon primoinfection with EU-11a are
strain-specific.
A number of NEs, some of them linear and other
conformational, have been described in different PRRSV
structural proteins, including GP2, GP3, and GP4 (52) of
PRRSV-1, GP5 of PRRSV-1 and PRRSV-2 (58, 59), and M
protein of PRRSV-2 (60). However, their role in the induction
of broadly reactive NAs is largely unknown (10). Only the NE
identified in the M protein of PRRSV-2 has been proven to play a
role in broadly neutralizing activity, with a single amino acid
necessary for the broad recognition (22). However, as the role of
M protein in the induction of NAs in PRRSV-1 remained largely
unidentified, it is not possible to know how important this NE is
in the induction of broadly reactive NAs in the case of PRRSV-1.July 2021 | Volume 12 | Article 691145
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considered immunodominant and responsible for the induction
of most of the NAs elicited upon infection (61). However, this
NE is highly variable (61), and most isolates display different
sequences and even deletions in this epitope (21), probably
because of a selective pressure during in vivo replication (51).
The preferential pig response against this highly variable NE
could help to explain the poor recognition of heterologous
viruses upon PRRSV infection (21) and, although the
specificity of the NAs generated against EU-11a was not
identified, it could be speculated that the NA response against
this virus was mainly directly against this epitope. On the
contrary, it is likely that Sp-3a exposes more efficiently
unidentified conserved NE, relevant for the recognition of
heterologous viruses. Unfortunately, up-to-date conserved NE
have not been mapped, with the only exception of the already
mentioned NE in M protein of PRRSV-2, and this lack of
knowledge makes it very difficult to identify the particular
sequence or sequences recognized by the pigs exposed to Sp-
3a virus.
Regardless the reasons that explain the differences in the
generation of broadly reactive NAs between the two viruses used
in our experiments, protection was better in groups in which
NAs against the heterologous virus were detected on the day of
the challenge. Thus, in experiment B, the initial immunization
with EU-11a elicited very low levels of cross-reactive NAs and
conferred very limited protection against a challenge with
heterologous PRRSV. However, viremia was less frequently
found in group B.5, in which cross-reactive NAs were detected
(although at low titers, i.e. GMT of NAs = 1.64 log2) than in any
other group.
On the contrary, in experiment A, an outstanding level of
protection, with a complete prevention of viremia, was observed
in five of the eight experimental groups. Consistent with this
finding, relatively significant titers of cross-reactive NAs were
detected the day of challenge in those five groups, with GMTs of
NAs ranging from 1.78 to 2.93 log2.
Nonetheless, the levels of cross-reactive NAs found in our
study are below the cutoff described in the literature for
protection against viremia (i.e., 1:8 or 3 log2). There might be
several explanations for this finding. First of all, it is possible that
NAs titers close to 3 log2, which has been proven to be sufficient
to protect sows from infection (15), are closer to the amount
needed to confer complete protection, or at least to prevent
viremia, in 140-day-old pigs than in young piglets. These
differences can be explained by a higher maturity of the
immune system and, most likely, by the lower susceptibility to
infection of the main target cell of PRRSV, PAM (62, 63). Thus, it
is conceivable that the lower viral load typically found in adults
(64) requires lower titers of NAs for an efficient control of the
infection (16).
On the other hand, in this study, cross-reactive NAs were
generated by natural infection instead of being passively
transferred. That means that it is possible that NAs were also
present in the mucosal surfaces, blocking the virus at the portal
of entry and avoiding the establishment of infection or, at least,Frontiers in Immunology | www.frontiersin.org 13viremia, regardless the titer of NAs in bloodstream. In this line of
thinking, it has been demonstrated that upon infection, local
immunity develops and PRRSV-specific antibodies can be found
in respiratory secretions (65), oral fluids, or bronchoalveolar
lavages (66).
Finally, it is likely that other components of the immune
response, and particularly, PRRSV-specific cellular immune
response, have developed upon immunization and contributed
to confer protection against a secondary heterologous PRRSV
exposure. This theory could also explain the high level of
protection observed in a few pigs in which cross-reactive NAs
titers were lower than 2 log2 (data not shown). This observation
has been made in other studies, and protection has been
attributed to cell-mediated immunity (11, 12). Unfortunately,
because of economic, logistic, and labor constrictions, it was not
possible to study the role of the cell-mediated immune response
in the protection observed, but we consider that cell-mediated
immunity might also have contributed significantly to the
control of the heterologous viruses.
Nonetheless, and regardless the contribution of cell-mediated
immunity to protection, it is remarkable that in two of the three
groups of experiment A in which only partial protection was
achieved, based on the recording of viremia in some pigs, cross-
reactive NAs were not detected at the time of challenge, whereas
in the third group (i.e., group A.4), only very low titers of NAs
(i.e. GMT of NAs = 0.72 log2) were found. Even more, in the only
pig of this group with cross-reactive NAs of 2 log2 at the time of
challenge, viremia was never detected, and the tonsil was
negative for PRRSV (data not shown), supporting the notion
that NAs played a relevant role in protection in our study.
Another interesting finding is the evolution of the NA titer
against the virus used for immunization (i.e., homologous) and
for challenge (i.e., heterologous) in the different experimental
groups. Thus, in experiment A, a booster against homologous
virus upon challenge was detected in the three groups in which
viremia was detected (although differences in NA titers were
statistically significant only in groups exposed to EU-17 and Sp-
27) and NAs titers remained unchanged in all other groups. On
the contrary, in experiment B, a booster was recorded in all
experimental groups, and the differences in NA titers were
statistically significant in all groups with the only exception of
pigs exposed to Sp-22. These results indicate that the viremia
subsequent to reinfection induces a secondary immune response,
whereas the absence of viremia, either due to sterilizing
immunity or accompanied by the distribution of the virus to
lymphoid tissues, does not change significantly the titer of NAs.
Thus, the presence or absence of a secondary immune response
might be an indirect indicator of protection.
Finally, it is unknown why some PRRSV-1 isolates generate
cross-reactive NAs, whereas others do not. The results of this
study encourage further studies aimed to characterize the
intrinsic properties of PRRSV-1 isolates that stimulate the
generation of broadly reactive NAs. In the same way, the two
PRRSV isolates characterized in this study represent a very useful
tool to decipher the components of the immune response
essential for the development of a protective immunity againstJuly 2021 | Volume 12 | Article 691145
Martı́nez-Lobo et al. Broadly NAs in PRRSV ProtectionPRRSV. Finally, the results of this study and the role of broadly
reactive NAs in protection should be confirmed in further studies
using a significant number of heterologous PRRSV isolates with
different biological properties and measuring cell-mediated
immunity to establish its role in protection.SUMMARY/CONCLUSION
In conclusion, the results reported here confirm that PRRSV-1
isolates differ in their ability to induce cross-reactive NAs and in
their ability to confer protection against heterologous
reinfections. According to the results of our study, PRRSV-1
isolates able to induce broadly reactive NAs as determined in
vitro could confer a better level of virological protection against
heterologous PRRSV infection in vivo. However, it has to be
mentioned that the correlation between the level of NAs and
protection was not perfect and that a few pigs without
measurable titers of NAs or with NA titers lower than those
established as the threshold for protection in passive transfer
studies were protected. This remarkable level of protection could
be explained by the contribution of other components of the
immune response, as cell-mediated immunity or mucosal
immunity. Nonetheless, the results of this study seem to
confirm that NAs, and particularly broadly reactive NAs, could
play a role in protection against PRRSV reinfections.DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be
made available by the authors, without undue reservation.Frontiers in Immunology | www.frontiersin.org 14ETHICS STATEMENT
The animal study was reviewed and approved by Comité de
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Dynamics and Differences in Systemic and Local Immune Responses After
Vaccination With Inactivated and Live Commercial Vaccines and Subsequent
Subclinical Infection With PRRS Virus. Front Immunol (2019) 10:1689.
doi: 10.3389/fimmu.2019.01689Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
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